Quarterly ResultMay 14, 2026, 06:12 AM
Raphael Pharmaceutical Q1 Net Loss Narrows 47% to $229K; Going Concern Risk
AI Summary
Raphael Pharmaceutical Inc. reported a net loss of $229,000 for the three months ended March 31, 2026, a 47% improvement from the $429,000 net loss in the prior year period. Operating loss also decreased by 48% to $223,000. However, the company faces substantial doubt about its ability to continue as a going concern, with cash and cash equivalents at only $1,000 as of March 31, 2026, and an accumulated deficit of $10.4 million. Management plans to raise additional capital to fund ongoing research and development and clinical trials.
Key Highlights
- Net loss decreased 47% to $229,000 for Q1 2026 from $429,000 in Q1 2025.
- Operating loss narrowed 48% to $223,000 in Q1 2026 from $425,000 in Q1 2025.
- Research and development expenses decreased 49% to $37,000.
- General and administrative expenses fell 47% to $186,000.
- Cash and cash equivalents stood at $1,000 as of March 31, 2026, down from $45,000 at year-end 2025.
- The company reported an accumulated deficit of $10.4 million and a going concern warning.
- Total current liabilities increased to $1.67 million from $1.49 million.
- Payables to related parties (officers) increased to $1.10 million from $0.95 million.